Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Prostate cancer patients treated with LHRH agonists (e.g., leuprolide) lose bone mineral
density. This is similar to post-menopausal osteoporosis. Risedronate is approved to prevent
osteoporosis. We hypothesize that risedronate may also be effective in prostate cancer
patients treated with LHRH agonists.